SCHEMBL16289643

SCHEMBL16289643

CCCCCCCC(CC)C(=O)Nc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.79
KMT2A Q03164 2/20 0.79
SMN1; SMN2 Q16637 2/20 0.79
ALDH1A1 P00352 2/20 0.79
MAPT P10636 1/20 0.79
MAPK1 P28482 1/20 0.79
HDAC8 Q9BY41 7/20 0.64
HDAC3 O15379 5/20 0.64
HDAC6 Q9UBN7 5/20 0.64
HDAC1 Q13547 4/20 0.64
HDAC2 Q92769 4/20 0.64
HDAC4 P56524 2/20 0.60
HDAC7 Q8WUI4 2/20 0.60
HDAC10 Q969S8 2/20 0.60
HDAC11 Q96DB2 2/20 0.60
HDAC9 Q9UKV0 2/20 0.60
HDAC5 Q9UQL6 2/20 0.60
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CA7 P43166 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29269298 1.00 MEN1 (0.79) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL29269467 1.00 MEN1 (0.79) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL11518363 0.98 MEN1 (0.81) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3923314 0.94 MEN1 (0.89) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL11652739 0.92 MEN1 (0.86) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL18882713 0.89 MEN1 (0.72) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3915908 0.89 MEN1 (0.68) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL16106143 0.87 MEN1 (0.73) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL7099035 0.87 MEN1 (0.78) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL28917678 0.86 ALDH1A1 (0.60) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2813227-A1 Compositions for treatment of cystic fibrosis and other chronic diseases Vertex Pharmaceuticals Incorporated (US) 2014-12-17 EP disclosed